昭衍新药 (603127.SH)

今开: 最高: 成交量:

昨收: 最低: 成交额:

+ 收藏

利润表(单季度)(昭衍新药)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2024年第三季度2024年第二季度2024年第一季度2023年第四季度2023年第三季度2023年第二季度2023年第一季度
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表
一、营业总收入(元) 485,799,506.29524,547,440.44324,809,103.67789,407,017.72575,002,491.20642,691,277.23369,386,010.95
 营业收入(元) 485,799,506.29524,547,440.44324,809,103.67789,407,017.72575,002,491.20642,691,277.23369,386,010.95
二、营业总成本(元) 474,671,792.13459,767,811.94293,294,646.96517,173,055.38390,640,555.41451,385,274.35262,811,341.25
 营业成本(元) 376,828,192.72373,266,447.05218,156,989.73471,245,512.56328,945,835.85385,079,713.36178,430,001.04
 研发费用(元) 23,245,993.9724,872,364.7022,967,298.3919,214,692.5520,706,257.4029,321,837.2927,611,585.58
 营业税金及附加(元) 1,509,963.283,014,928.052,369,721.321,935,277.542,440,444.311,635,255.991,665,149.61
 销售费用(元) 7,239,448.166,312,595.465,850,463.876,282,474.706,466,520.306,504,940.485,361,173.05
 管理费用(元) 80,385,096.7884,389,006.6071,961,656.6951,018,026.7076,743,804.3777,949,191.3474,543,757.54
 财务费用(元) -14,536,902.78-32,087,529.92-28,011,483.04-32,522,928.67-44,662,306.82-49,105,664.11-24,800,325.57
  其中:利息费用(元) 579,389.15595,089.51653,474.98716,158.11745,040.01826,862.69854,085.47
  其中:利息收入(元) 20,894,856.6432,563,233.2729,068,900.7534,186,800.8947,455,286.5030,221,335.3330,639,976.24
 资产减值损失(元) 19,733,715.33-18,949,498.95-26,264,433.00-25,813,609.98-5,180,544.47179,377.75-417,677.50
 信用减值损失(元) -3,310,405.35-6,298,322.30-1,868,335.27-7,134,897.75897,074.23-1,993,808.82-2,090,412.59
三、其他经营收益
 加:公允价值变动收益(元) 66,788,721.0052,822,749.43-310,012,920.11-137,127,582.7689,157,007.38-296,112,546.1998,441,604.72
 加:投资收益(元) 3,601,008.8821,047,142.496,972,038.252,486,164.351,298,127.505,329,415.17514,120.05
  其中:对联营企业和合营企业的投资收益(元) -16,030,035.39-558,720.76-516,133.40-874,093.21-909,070.59-769,932.19
 资产处置收益(元) ---1,019.77---
 其他收益(元) 9,552,973.562,920,508.106,650,918.6910,366,325.244,779,205.583,760,977.8411,347,382.60
四、营业利润(元) 107,493,727.58115,853,533.43-293,008,274.73115,011,381.21275,245,834.39-97,530,581.37214,369,686.98
 加:营业外收入(元) -12,892.2898,694.1910,364.83150,780.6413,982.22200,577.0021,369.30
 减:营业外支出(元) 21,997.78173,319.29132,105.74196,905.03210,307.9563,247.8262,132.34
五、利润总额(元) 107,458,837.52115,778,908.33-293,130,015.64114,965,256.82275,049,508.66-97,393,252.19214,328,923.94
 减:所得税费用(元) 9,464,531.3214,653,621.40-19,766,412.5749,609,697.8338,360,676.25808,656.1926,618,845.32
六、净利润(元) 97,994,306.20101,125,286.93-273,363,603.0765,355,558.99236,688,832.41-98,201,908.38187,710,078.62
(一)按经营持续性分类
  持续经营净利润(元) 97,994,306.20101,125,286.93-273,363,603.0765,355,558.99236,688,832.41-98,201,908.38187,710,078.62
(二)按所有权归属分类
  归属于母公司股东的净利润(元) 99,435,565.54102,479,834.34-272,222,474.9969,394,206.74236,971,204.96-97,132,500.76187,759,654.85
  少数股东损益(元) -1,441,259.34-1,354,547.41-1,141,128.08-4,038,647.75-282,372.55-1,069,407.62-49,576.23
 扣除非经常性损益后的净利润(元) 84,926,745.3382,271,793.65-280,666,741.3426,476,479.47234,201,796.98-107,861,663.87184,748,130.28
七、每股收益
 一、基本每股收益(元) 0.140.13-0.360.090.27-0.180.35
 二、稀释每股收益(元) 0.140.13-0.360.090.27-0.180.35
八、其他综合收益(元) -7,884,103.612,161,124.32863,793.54-5,223,435.35-3,067,928.5317,654,771.30-4,402,644.75
 归属于母公司股东的其他综合收益(元) -7,884,103.612,161,124.32863,793.54-5,223,435.35-3,067,928.5317,654,771.30-4,402,644.75
九、综合收益总额(元) 90,110,202.59103,286,411.25-272,499,809.5360,132,123.64233,620,903.88-80,547,137.08183,307,433.87
 归属于母公司所有者的综合收益总额(元) 91,551,461.93104,640,958.66-271,358,681.4564,170,771.39233,903,276.43-79,477,729.46183,357,010.10
 归属于少数股东的综合收益总额(元) -1,441,259.34-1,354,547.41-1,141,128.08-4,038,647.75-282,372.55-1,069,407.62-49,576.23
公告日期 2024-10-312024-08-312024-04-302024-03-292023-10-312023-08-312023-04-28
审计意见(境内) 标准无保留意见

前瞻产业研究院